Puroxan

Ország: Örményország

Nyelv: angol

Forrás: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Termékjellemzők Termékjellemzők (SPC)
26-03-2018

Aktív összetevők:

doxofylline

Beszerezhető a:

M & H Manufacturing Co. Ltd.

INN (nemzetközi neve):

doxofylline

Adagolás:

400mg

Gyógyszerészeti forma:

tablets

Recept típusa:

Prescription

Termékjellemzők

                                PUROXAN TABLET
SUMMARY OF PRODUCT CHARACTERISTICS
(DOXOFYLLINE 400 MG TABLET) APPENDIX 1.9
1.
NAME OF THE MEDICINAL PRODUCT
Puroxan
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains Doxofylline 400 mg
For excipients, see 6.1.
3.
DOSAGE FORM
Tablets
4.
CLINICAL CHARACTERISTICS
4.1
THERAPEUTIC INDICATIONS
PUROXAN is indicated for the treatment of chronic respiratory disease,
such as
Bronchial Asthma and Chronic Obstructive Pulmonary Disease (COPD).
4.2
DOSAGE AND METHOD OF ADMINISTRATION
_ADULTS: _
1 tablet (400 mg) 2 times daily.
The dosage may be increased to 1 tablet 3 times daily according to the
prescribing
physician.
The dosage (800 mg/day) may be decreased according to medical
prescription in
the very elderly patients with concomitant cardiovascular, hepatic,
renal and gastric
diseases, to ½ tablet 2 times daily.
4.3
CONTRAINDICATIONS
This product is contraindicated in individuals who have shown
hypersensitivity to
its components. It is also contraindicated in lactating women.
4.4
SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE
The half-life of xanthine derivatives is influenced by a number of
known variables.
It may be prolonged in patients with severe hepatic insufficiency, in
patients with
end stage congestive heart failure, in those affected with chronic
obstructive lung
disease or concomitant infections, and in those patients taking
certain other drugs
(erythromycin, troleandomycin, lincomycin and other antibiotics of the
same
group, allopurinol, cimetidine, propanolol, and anti-flu vaccine). In
these cases, a
lower dose of Doxofylline may be needed.
Phenytoin, other anticonvulsants and smoking may cause an increase in
clearance
with a shorter mean half-life: in these cases higher doses of
Doxofylline may be
needed.
Laboratory monitoring of plasma concentration of Doxofylline is
recommended in
all the above situations.
Use with caution in patients with hypertension, heart disease,
hypoxemia,
hyperthyroidism, chronic right ventricular failure, congestive heart
failure, liver
disease, ren
                                
                                Olvassa el a teljes dokumentumot
                                
                            

Dokumentumok más nyelveken

Betegtájékoztató Betegtájékoztató orosz 26-03-2018

A termékkel kapcsolatos riasztások keresése

Dokumentumelőzmények megtekintése